Biomarker: PD-L1

Histology type: endometrial carcinoma

Country: Korea

Region: Seoul

Study type: retrospective

Followed up time :

Conclusion: The high PD-L1/CD8 ratio and the high expression of PD-L1 on immune cells were independent poor prognostic factors for PFS in endometrial cancer, providing insights into the tumor microenvironment.

Sample type : tissue

Sample method: immunohistochemistry

Expression pattern : PD-L1/CD8 ratio high on immune cells

Expression elevation: PD-1 expression was estimated as the percentage of PD1-positive ICs relative to the total number of ICs in each compartment. Its expression was estimated as the percentage of TCs showing membranous PD-L1 staining and as the percentage of PD-L1-positive ICs showing cytoplasmic or membranous staining relative to the total number of ICs occupying each compartment was recorded for TCs and ICs. the IHC expression was subdivided into low and high levels using optimal cut-off points determined by the K-Adaptive partitioning method.

Statictics: Mean (SD)

Cohort age: 53.0 ± 10.4

Funtion Uniprot: Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).4 Publications The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

UniProt ID: Q9NZQ7

UniProt Link: https://www.uniprot.org/uniprotkb/Q9NZQ7/entry

Biological function from UniProt: Adaptive immunity, Immunity

Molecular function from UniProt:

Tissue specificity from UniProt: Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes

Subcellular UniProt: #Cell membrane #Endosome #Membrane

Alternative name from UniProt:

Recommended name: Programmed cell death 1 ligand 1

Gene name from HGNC: CD274 (B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1)

HPA class: Cancer-related genes CD markers Disease related genes FDA approved drug targets

AlphaFold DB: Q9NZQ7

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/Q9NZQ7

Induction: Up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation. Up-regulated in B-cells activated by surface Ig cross-linking.

HPA link: https://www.proteinatlas.org/ENSG00000120217-CD274

Tissue specificity RNA from HPA: Tissue enhanced (lung)

Tissue expression from HPA: High expression in placental trophoblasts.

Single cell type specificity Cell type enhanced (Langerhans cells, Syncytiotrophoblasts, monocytes, granulocytes, Extravillous trophoblasts)

Immune cell specificity: Immune cell enhanced (basophil)

Subcellular summary HPA Located in Nucleoplasm, Plasma membrane, Actin filaments

Cancer prognostic summary HPA Prognostic marker in colorectal cancer (favorable) and breast cancer (favorable)

Pathology link: https://www.proteinatlas.org/ENSG00000120217-CD274/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000120217-CD274/pathology/endometrial+cancer

Disease: No disease ID

Note1: Truncation of the 3'-untranslated (3'-UTR) region of CD274 transcripts leads to elevated expression of CD274 in multiple cancers including T-cell leukemia, diffuse large B-cell lymphoma and stomach adenocarcinoma (PubMed:27281199). Disruption of 3'-UTR region is caused by structural variants that stabilize CD274 transcripts, leading to overexpression (PubMed:27281199). Increased expression in tumors promotes immune evasion and tumor cell growth by allowing malignant cells to escape destruction by the immune system (PubMed:27281199)

OMIM: 605402

OMIM link2: https://www.omim.org/entry/605402

HGNC ID: HGNC:17635

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635